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Abstract
Background: Anaemia is a very common problem in patients with end-stage kidney disease (ESKD) and the use of
erythropoietin-stimulating agents (ESA) has revolutionised its treatment. Residual renal function (RRF) is associated
with a reduction in ESA resistance and mortality in chronic dialysis. The primary aim was to establish whether RRF
has an association with ESA dose requirements in ESKD patients receiving chronic dialysis.
Methods: A single center, cross-sectional study involving 100 chronic dialysis patients was conducted from December 2015
to May 2016. Participants were divided into two groups depending on presence of RRF, which was defined as a 24-h urine
sample volume of ≥ 100 ml. Erythropoietin resistance index [ERI = total weekly ESA dose (IU)/weight (kg)/haemoglobin
concentration (g/dL] was used as a measure of ESA dose requirements.
Results: There was no difference in ERI between those with RRF as compared to those without (9.5 versus 11.0,
respectively; P = 0.45). Also, ERI did not differ between those receiving haemodialysis as compared with peritoneal
dialysis (10.8 versus 10.2, respectively; P = 0.84) or in those using renin-angiotensin system (RAS) blockers as compared
with no RAS blocker use (11.6 versus 9.2, respectively; P = 0.10). Lower ERI was evident for those with cystic kidney
disease as compared to those with other causes of ESKD (6.9 versus 16.5, respectively; P = 0.32) although this did not
reach statistical significance. Higher ERI was found in those with evidence of systemic inflammation as compared to
those without (16.5 versus 9.5, respectively; P = 0.003).
Conclusions: There was no association between RRF and ESA dose requirements, irrespective of dialysis modality, RAS
blocker use, primary renal disease or hyperparathyroidism.
Keywords: Residual renal function, Erythropoietin resistance index, Chronic dialysis, Erythropoietin stimulating agent
dose requirements
Background
Anaemia is a very common problem in end-stage kidney
disease (ESKD) and has been reported to occur in up to
75% of patients at presentation [1]. The treatment of
anaemia with erythropoietin-stimulating agents (ESA) in
ESKD has revolutionised its treatment, but its use has
been tempered by higher risks of cardiovascular morbid-
ity and mortality [2]. This has resulted in a more
judicious prescription of ESA in chronic dialysis patients
with more conservative haemoglobin (Hb) target ranges.
The focus of treatment of anaemia has shifted from re-
ducing cardiovascular event rates to improving quality
of life.
A recent meta-analysis found no difference in Hb con-
centrations between haemodialysis (HD) and peritoneal
dialysis (PD) patients [3]; however, treatment response
to ESA may vary depending on dialysis modality. It has
been reported that PD patients tend to have lower ESA
dose requirements than their HD counterparts [4, 5].
Possible explanations for this include less frequent
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phlebotomy, subcutaneous administration of ESA that is
associated with up to a third saving in dose and finally
the preservation of residual renal function (RRF) [6].
The most common factors associated with increased
dose requirements in chronic dialysis patients are iron
deficiency and chronic inflammation. Other causes
include malnutrition, hyperparathyroidism, poor vascu-
lar access, older age, dialysis vintage and use of renin-
angiotensin-system (RAS) blockers [7, 8].
A very important factor associated with reduced ESA
dose requirements is RRF. There is no universally ac-
cepted definition for RRF, although most studies make
use of a urine volume greater than 100 ml to 250 ml per
day [9, 10]. The CANUSA study reported that for every
250 ml of urine output per day, mortality was reduced
by 36% [9]. Other studies reported that the risk of death
was reduced by 11–23% for each 1 ml/min/1.73m2 of
RRF [10, 11]. It has been found that RRF is better pre-
served in PD than HD [12]. This may be due to
improved haemodynamic stability during ultrafiltration
in PD as compared to HD. Therefore, RRF may partially
explain why PD patients have reduced ESA dose require-
ments as well as less ESA resistance.
Erythropoietin resistance index (ERI), which is defined
as the weekly dose of ESA divided by patient weight and
corrected for the Hb concentration, is a measure of a
patient’s response to ESA. It has become routine for
studies to report ERI as a measure of ESA dose require-
ments. A recent study found that a strong linear rela-
tionship exists between ERI and weight-adjusted ESA
dose using a universal formula [13]. However, it is
important to take cognisance of the timing of the ESA
initiation and the value of the accompanying Hb concen-
tration when calculating the ERI. At the time of initi-
ation, a higher ERI measurement may be evident as
lower Hb concentrations may be present. As the Hb
concentration increases in response to the ESA, the ERI
will decrease [14]. Once target Hb concentrations are
achieved, the ESA dose is unlikely to change and the
ERI calculation will remain relatively constant. There-
fore, an ERI which is high at the time of ESA initiation
may wrongly be interpreted as ESA resistance. ERI
should only be used in patients established on relatively
constant ESA doses to avoid misinterpretation and in-
appropriate increases in dose. It has been reported that
the ERI is significantly lower in patients with RRF when
compared to those with anuria [15, 16].
The primary aim of this study was to establish
whether RRF in chronic dialysis patients was associ-
ated with reduced ESA dose requirements using ERI
as a measure of response. Secondary outcomes in-
cluded comparisons of ERI between dialysis modality,
route of ESA administration, primary renal disease
and RAS blocker use.
Methods
Study design, setting and participants
A cross-sectional study involving 100 chronic HD and
PD patients was undertaken at Tygerberg Academic
Hospital and its associated satellite dialysis units in the
Western Cape province of South Africa, during the
period of December 2015 to May 2016. All chronic dia-
lysis patients ≥ 18 years of age, with the ability to give
informed consent and on stable ESA treatment for at
least 3 months were included. Patients were excluded if
they were receiving dialysis for acute kidney injury or
delayed graft function, actively bleeding, current infec-
tion or there was an inability to collect a 24-h urine
sample (Fig. 1). All patients included were free of pri-
mary haematological diseases.
Data regarding demographics, primary renal disease,
co-morbid diseases, dialysis modality and vintage, dry
weight and drug prescription were collected from clin-
ical records. Laboratory data collected included Hb,
albumin, ferritin, transferrin saturation, C-reactive pro-
tein (CRP) and parathyroid hormone (PTH). RRF was
measured using a urine sample collected over 24-h. In
HD patients, it was measured during the longest inter-
dialytic period and in PD patients during any 24-h
period.
The patients were then divided into two groups de-
pending on presence or absence of RRF, defined as the
production of at least 100 ml of urine in 24 h (Fig. 1).
ERI for each patient was calculated as the current
weekly erythropoietin dose per kilogram of body
weight (IU/kg/week) divided by the Hb concentration
(g/dL). All the patients received ESA subcutaneously. La-
boratory evidence of systemic inflammation was defined
as the presence of all the following: a low serum albumin
(< 35 g/L), raised serum CRP (> 10 mg/L) and raised
serum ferritin (> 150 ng/mL). Hyperparathyroidism was
classified according to the Kidney Disease Improving Glo-
bal Outcomes (KDIGO) clinical practice guideline recom-
mendations for the management of chronic kidney
disease-mineral and bone disorder (CKD-MBD). Those
with a PTH value of 2–9 times the upper limit of normal
for the assay were regarded as being in the target range
(17.0–76.5 pmol/L). Those with PTH < 17.0 pmol/L or
>76.5 pmol/L were regarded as being over-suppressed or
having hyperparathyroidism, respectively.
Statistical analysis
Means ± standard deviations were used to summarize
data with a normal distribution and medians and inter-
quartile ranges (IQR) for data that did not have a normal
distribution. Histograms, bar graphs and box-and-
whisker plots were used where appropriate. Chi-squared
and Fisher’s exact tests were used to compare categorical
data. Both unadjusted and adjusted analysis with multi-
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linear regression for age, sex and race were used for dia-
lysis modality, route of ESA administration, PTH status,
RAS blocker use and primary renal disease. Where con-
tinuous variables had a normal distribution, t-tests were
used to compare means, and if not normally distributed
were analysed using Mann-Whitney-U tests. A signifi-
cant P-value was set at P < 0.05. SPSS version 24 was
used for data analysis.
Results
A total of 100 patients were included in the final ana-
lysis. The mean for age was 41 ± 10.5 years and 57%
were female. Most of the patients were of mixed ances-
try (65%). The most common primary kidney disease
was ESKD (cause unknown) (66%), followed by renal
vascular disease (14%). Two-thirds (67%) of the patients
were receiving chronic HD as their dialysis modality
while the rest were receiving chronic ambulatory PD.
A total of 36 patients had RRF. It was more common
in PD patients than in those receiving HD as their
dialysis modality (58.3% versus 41.7%, respectively; P <
0.01). Patients with RRF were younger (37.4 versus
43.0 years old; P = 0.01), and had a shorter dialysis vin-
tage (34 versus 64 months; P < 0.01). More patients with
RRF were on diuretics (75.0% versus 31.3%, P < 0.01) and
phosphate binders (94.4% versus 73.4%, P = 0.01). There
was a trend toward less RAS blocker use in those with
RRF as compared to those without (38.9% versus 59.4%,
respectively; P = 0.05). There were no statistical signifi-
cant differences in any of the laboratory serum measure-
ments (Table 1).
With respect to our primary outcome, ERI did not dif-
fer in those with or without RRF (9.5 [IQR 7.0–15.3] ver-
sus 11.0 [IQR 6.3–16.2], respectively; P = 0.45). The
median dose of ESA was identical in each group
(6000 IU per week). When dividing RRF into quartiles,
there were no statistical differences in ERI between those
with higher volumes of RRF as compared to those with
lower volumes or no RRF (P = 0.82) (Figs. 2 and 3). Also,
a statistically significant association was not identified
between ERI and RRF volume using linear regression
analysis (P = 0.27).
ERI did not differ by dialysis modality (10.8 [IQR 8.5–
14.3] in PD versus 10.2 [IQR 5.9–16.0] in HD, P = 0.84).
Lower ERI were evident for those with cystic kidney dis-
ease as compared to those with other causes of ESKD
(6.9 [IQR 3.9–13.2] versus 16.5 [IQR 12.0–17.9], respect-
ively; P = 0.43) but it did not reach statistical signifi-
cance. There was no statistically significant difference
in ERI in those with or without RAS blocker use
(11.6 [IQR 7.9–16.7] versus 9.2 [IQR 6.1–15.2], re-
spectively; P = 0.10).
ESA, erythropoietin-stimulating agent; HD, haemodialysis; PD, peritoneal dialysis; 
RRF, residual renal function
Total of 130 HD and PD patients screened  
100 patients included:
HD = 67, PD = 33
30 patients excluded:
- Inability to collect and/or return 24-hour 
urine sample
- Not using ESA
- Not on stable ESA dose
- Inability to gain informed consent 
24-hour urine sample collection
RRF ≥100 mL
N=36
RRF <100 mL
N=64
Fig. 1 Flow diagram of patients screened and included in the final analysis
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Table 1 Comparisons of clinical baseline characteristics in those with and without RRF
Parameter RRF present RRF absent P-value
Number of patients 36 64 –
Age in years, mean ± SD 37.4 ±10.7 43 ±10.2 0.01
Sex, n (%)
Male 15 (41.7) 28 (43.8) 0.84
Female 21 (58.3) 36 (56.3)
Race, n (%)
Mixed ancestry 23 (63.9) 42 (65.6) 0.15
Caucasian 6 (16.7) 16 (25.0)
Black 5 (13.9) 6 (9.4)
Indian 2 (5.6) 0 (0)
Underlying kidney disease, n (%)
ESKD (cause unknown) 23 (63.9) 43 (67.2) 0.78
Renal vascular disease 6 (16.7) 8 (12.5)
Cystic kidney disease 1 (2.8) 3 (4.7)
Autoimmune disease 2 (5.6) 2 (3.1)
Other and unknown 4 (11.1) 8 (12.5)
Mode of dialysis, n (%)
HD 15 (41.7) 52 (81.3) <0.01
PD 21 (58.3) 12 (18.8)
Dialysis vintage (months) 34 (10.5–53) 64 (41–125) <0.01
ESA dose (IU per week) 6000 (5000–6000) 6000 (3000–9000) 0.46
Route of ESA administration, n (%)
SC 36 (100) 64 (100) –
Chronic medication, n (%)
RAS blocker 14 (38.9) 38 (59.4) 0.05
Diuretic 27 (75.0) 20 (31.3) <0.01
Phosphate binder 34 (94.4) 47 (73.4) 0.01
Vitamin D 9 (25.0) 27 (37.5) 0.08
Iron therapy 35 (97.2) 63 (98.4) 0.46
Oral 31 (86.1) 50 (78.1)
IV 4 (11.1) 13 (20.3)
Laboratory parameters
Haemoglobin (g/dL) 10.1 (9.2–11.1) 10.1 (8.8–10.8) 0.54
Albumin (g/L) 39 (34–40) 37 (33–40) 0.28
Ferritin (ng/mL) 545.0 (299–759.5) 469.0 (237.5–781.5) 0.99
Transferrin saturation (%) 22 (15–30) 23 (16–29) 0.49
CRP (mg/L) 15 (4–29) 20 (4–45) 0.48
PTH (pmol/L) 41.5 (18.6–73.2) 50.2 (17.6–117.4) 0.70
Systemic inflammation, n (%) 3 (8.3) 11 (17.1) 0.21
Values expressed in a range in parentheses refer to interquartile ranges; single values refer to percentage of the group population. RRF residual renal function; SD
standard deviation; ESKD end-stage kidney disease; HD haemodialysis; PD peritoneal dialysis; ESA erythropoietin-stimulating agent; IU international units; SC
subcutaneous; RAS renin angiotensin system; CRP C-reactive protein; PTH parathyroid hormone. Systemic inflammation was defined as serum ferritin >150 ng/mL
and serum CRP >10 mg/L and serum albumin <35 g/L
Louw and Chothia BMC Nephrology  (2017) 18:336 Page 4 of 8
A total of 14 patients fulfilled our criteria for systemic
inflammation. Of these, 11 (78.6%) had no RRF and had
higher ERI when compared to those without systemic
inflammation (16.5 [IQR 11.0–18.7] versus 9.5 [IQR
6.0–14.9], respectively; P = 0.003). A statistically
significant association between ERI and systemic inflam-
mation persisted after adjusting for dialysis vintage using
multiple linear regression, P = 0.049). When comparing
ERI with PTH <17.0 pmol/L (over-suppressed), 17.0–
76.5 pmol/L (target range) and >76.5 pmol/L
Fig. 2 Primary outcome: Erythropoietin resistance index and residual renal function
Fig. 3 A comparison of quartiles of residual renal function and its association with erythropoietin resistance index
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(hyperparathyroidism), ERI tended to be higher in the
over suppressed group but there were no statistical sig-
nificant differences (Tables 2 and 3).
Discussion
In our study, we found no association between RRF and
ESA dose requirements as measured using ERI. This
finding contrasts with some larger studies that identified
less ESA requirements in those patients with preserved
RRF [15, 16]. These studies were done mainly in HD
patients. Another study that was conducted in PD
patients reported no influence of RRF on ERI [17]. A re-
cent, large observational study reported that ERI was
higher for patients on HD as compared to those on PD
[5]. It is unclear whether patients included were on
stable ESA doses and what the effect RRF may have had.
However, the authors mention that more frequent phle-
botomy and the intravenous administration of ESA
might have elevated the ESA dose requirements in the
HD group. In contrast, all our participants received ESA
by the subcutaneous route and were on stable ESA doses
for at least 3 months prior to recruitment therefore lim-
iting the effect that these two potential confounding var-
iables may have had on ERI.
Our study population was younger and mainly of
mixed ancestry when compared to other studies [18, 19].
Most were receiving HD with fewer PD patients in-
cluded due to logistical issues related to the collection
and/or the return of 24-h urine samples and an
inability to obtain informed consent. RRF was mostly
present in our PD patients who also had the shortest
dialysis vintage. These findings reflect our PD-first
policy.
We found a strong association between higher ERI
and laboratory evidence of systemic inflammation.
Others have reported similar findings [5, 17]. None of
our patients were iron deficient or had an obvious infec-
tion. This systemic inflammation could possibly be due
to occult infection or dialysis-related factors. We have
previously reported a strong association between occult
periodontal disease and systemic inflammation in our
chronic dialysis population [20]. A high ERI may there-
fore be a marker of systemic inflammation and clinicians
should be cautious when deciding to increase the ESA
dose, as this class of drugs has been associated with
increased risk of cardiovascular events.
We found no association between ERI and dialysis
modality, RAS blocker use, the underlying primary renal
disease or hyperparathyroidism. A recent meta-analysis
also reported no difference relative to dialysis modality
[3], although some individual studies have reported dif-
ferences [4, 5]. There was a trend toward less RRF in
those with RAS blocker use. Although there have been
studies suggesting that RAS blocker use may preserve
RRF, others have found no benefit [21, 22]. It may be
that better volume control in those with RRF resulted in
less prescription of antihypertensive drugs including
RAS blockers. RAS blockers had no significant effect on
ERI. The influence of RAS blockers on ESA resistance
remains controversial. Various pathogenic mechanisms
have been implicated [23, 24]; however, observational
studies have reported mixed results [25–27]. Nonethe-
less, a dose-response relationship does exist [28] and
therefore when other common causes for ESA resistance
Table 2 Primary and secondary outcomes
Parameter Number of
patients
Median ERI IQR P-value
Primary Outcome
Residual renal function
Present 36 9.5 (7.0–15.3) 0.45
Absent 64 11.0 (6.3–16.2)
Secondary Outcomes
Dialysis modality
HD 67 10.8 (8.5–14.3) 0.84
PD 33 10.2 (5.9–16.0)
RAS blocker use 52 11.6 (7.9–16.7)
ACE inhibitor 43 11.8 (8.1–16.8) 0.10
ARB 9 11.0 (6.0–13.7)
No RAS blocker
use
48 9.2 (6.1–15.2)
PTH category (pmol/L)
< 17 19 13.5 (6.5–16.8) 0.73
17–76.5 34 9.6 (6.2–14.9)
> 76.5 28 9.1 (6.8–15.3)
Systemic inflammation
Present 14 16.5 (11.0–18.7) <0.01
Absent 86 9.5 (6.0–14.9)
Underlying kidney disease
ESKD (cause
unknown)
66 10.8 (7.8–15.4) 0.32
Renal vascular
disease
14 8.4 (5.2–14.3)
Cystic kidney
disease
4 6.9 (3.9–13.2)
Autoimmune
disease
4 16.5 (12.0–17.9)
Other and
unknown
12 9.1 (6.4–15.5)
ERI erythropoietin resistance index; IQR interquartile range; HD haemodialysis;
PD peritoneal dialysis; ACE angiotensin-converting enzyme; RAS renin
angiotensin system; PTH parathyroid hormone; ESKD end-stage kidney disease.
‘Other’ refers to reflux nephropathy, single kidney, renal cortical necrosis,
pre-eclampsia, drug overdose and unknown aetiology. Systemic inflammation
was defined as serum ferritin >150 ng/mL and serum CRP >10 mg/L and
serum albumin <35 g/L
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have not been identified, reducing or stopping RAS
blockers is a reasonable next step.
The lower ERI in polycystic kidney disease patients is
expected as it is thought that interstitial cells adjacent to
the walls of the proximal-type cysts can produce
erythropoietin, resulting in higher Hb concentrations
and therefore lower ESA requirements [29]. Our patients
with autoimmune disease tended to have higher ERI that
may be related to systemic inflammation.
Hyperparathyroidism is frequently listed as a cause for
ESA resistance; however, we did not identify any associ-
ation with PTH level. In fact, our patients classified as
having secondary hyperparathyroidism tended to have a
lower ERI. It is thought that the high-turnover bone
disease from secondary hyperparathyroidism may cause
bone marrow fibrosis. This has not been found in animal
models of secondary hyperparathyroidism [30] and it
therefore seems increasingly unlikely that hyperparathyr-
oidism contributes to ESA resistance.
Strengths and limitations
Our study has some limitations. This was a relatively
small, single center study, with fewer PD patients. The
inclusion of 24-h urine sample creatinine clearance and/
or β2-microglobulin may have better characterised RRF.
However, the interpretation of our ERI measurements is
more reliable because of the uniform route of ESA ad-
ministration and the inclusion of only those on relatively
stable ESA doses.
Conclusions
In summary, we found no association between RRF and
ESA dose requirements as measured using ERI, irre-
spective of dialysis modality, RAS blocker use, primary
renal disease or hyperparathyroidism. However, the pres-
ence of systemic inflammation had a significant effect on
ERI. Therefore, in those with high ESA dose require-
ments, an active search for a source of inflammation
should be conducted.
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